Related Experiment Video

Updated: Oct 1, 2026

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

Atopy in children in relation to BCG vaccination and genetic polymorphisms at SLC11A1 (formerly NRAMP1) and D2S1471

J S Alm1, C B Sanjeevi, E N Miller

  • 1Department of Medicine, Unit of Clinical Allergy Research, Karolinska Hospital and Institutet, Stockholm, Sweden. Johan.Alm@sos.ki.se

Genes and Immunity
|April 18, 2002
PubMed

Insights

The SLC11A1 gene may influence atopy risk in BCG-vaccinated children. Specific D2S1471 alleles increased atopy and IgE responses to allergens, highlighting gene-environment interactions in disease susceptibility.

Area of Science:

  • Immunogenetics
  • Pediatric Allergy
  • Molecular Epidemiology

Background:

  • Atopy, a predisposition to allergic diseases, is influenced by genetic and environmental factors.
  • Bacille Calmette-Guérin (BCG) vaccination is known to modulate immune responses.
  • The SLC11A1 gene (formerly NRAMP1) plays a role in innate immunity and has been investigated for its association with various diseases.

Purpose of the Study:

  • To investigate the influence of the SLC11A1 gene on the association between BCG vaccination and atopy in children.
  • To examine the relationship between SLC11A1 polymorphisms, BCG status, and the development of atopic symptoms and IgE responses.

Main Methods:

  • Genotyping of 179 BCG-vaccinated and 307 unvaccinated children (3-8 years old) with atopic heredity for SLC11A1 promoter polymorphism (GTn) and linked microsatellite D2S1471.
  • Assessment of associations between genotypes, atopic symptoms, and allergen-specific IgE levels in relation to BCG vaccination status.
  • Analysis of linkage disequilibrium between SLC11A1 GTn and D2S1471.

Main Results:

  • Atopy distribution was similar between BCG-vaccinated and unvaccinated groups concerning SLC11A1 GTn-alleles.
  • In BCG-vaccinated children, D2S1471 genotype was associated with atopy (allele 5: OR 2.6) and IgE responses to airborne allergens (OR 4.3).
  • No linkage disequilibrium was found between SLC11A1 GTn and D2S1471, precluding haplotype analysis.

Conclusions:

  • BCG vaccination status can unmask genetic risk factors for atopy near the SLC11A1 locus.
  • The findings suggest significant genotype by environment interactions in determining susceptibility to atopy.
  • The D2S1471 marker, linked to SLC11A1, may represent a genetic risk factor for atopy in BCG-vaccinated children.

More Related Videos

Assessment of Lymphocyte Migration in an Ex Vivo Transmigration System10:25

Assessment of Lymphocyte Migration in an Ex Vivo Transmigration System

Published on: September 20, 2019

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Asthma I: Introduction01:28

Asthma I: Introduction

Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Diversity of Antigen Receptors01:28

Diversity of Antigen Receptors

Antigen receptors are essential components of the immune system crucial in defending the body against foreign invaders. These receptors are present on the surface of B and T cells, enabling them to recognize antigens and mount an appropriate immune response.
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
Cross-reactivity00:42

Cross-reactivity

Overview
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...